Phenotypes Associated with This Genotype

Genotype
MGI:4458207

• Allelic Composition: Tcf3^{tm1(TCF3/HLF)Homy}/Tcf3⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

mortality/aging ( J:160392 )

N • pIpC-treated mice have a normal lifespan

increased susceptibility to induced morbidity/mortality ( J:160392 )

• mice treated with pIpC and Moloney murine leukemia virus (MMLV) exhibit increased morbidity and mortality with all mice dying by 6 months of age unlike with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

hematopoietic system

hematopoietic system phenotype ( J:160392 )

N • pIpC-treated mice exhibit no abnormalities in peripheral blood

abnormal B cell differentiation ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

increased B cell number ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

neoplasm

increased incidence of induced tumors ( J:160392 )

• mice treated with pIpC and Moloney murine leukemia virus (MMLV) exhibit increased morbidity and mortality with all mice dying by 6 months of age unlike with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

• mice treated with pIpC and MMLV develop only acute B-progenitor and lineage marker negative leukemias as early as 2.6 months compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes that develop T cell leukemias at 4 to 6 months

homeostasis/metabolism

abnormal thrombosis ( J:160392 )

• pIpC-treated and Moloney murine leukemia virus (MMLV)-exposed mice develop microthrombi

immune system

abnormal B cell differentiation ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes

increased B cell number ( J:160392 )

• pIpC-treated mice exhibit an increase in B cell precursors in the bone marrow compared with similarly treated Tcf3^{tm1(TCF3/HLF)Homy} heterozygotes